Das Projekt "Teilprojekt 4^Herstellung hochaffiner rekombinanter Antikörper für den polyzyklischen aromatischen Kohlenwasserstoff Benzo(a)pyren^Teilprojekt 3, Teilprojekt 2" wird/wurde gefördert durch: Bundesministerium für Bildung und Forschung. Es wird/wurde ausgeführt durch: Universität Halle-Wittenberg, Institut für physiologische Chemie.
Das Projekt "Monoclonal antibody-targeted carbon nanobues against cancer (ANTICARB)" wird/wurde gefördert durch: Kommission der Europäischen Gemeinschaften Brüssel. Es wird/wurde ausgeführt durch: University College London.Objective: ANTICARB attempts to exploit the advantages offered by a novel nanotechnology platform carbon nanotubes and apply them to a clinically established therapeutic modality targeted antibody therapy for the creation of hybrid nanotechnology-based monoclonal antibody targeted cancer therapeutics. ANTICARB combines two emerging technologies, antibody and nanotube technology, in a way that will allow safe development of antibody-nanotube conjugates and explore their swift translation into a clinical oncology setting. By combining proven, clinically used, anti-cancer agents' antibodies with a novel nanotechnology-based platform made of advanced nanomaterials, ANTICARB aims at enhancing the therapeutic potency of the antibody and establish a new paradigm for oncology therapeutics. The ability of carbon nanotube technology to transport antibodies into the tumour cell cytoplasm may lead to validation of specific intracellular targets for oncology. This objective will be reached by adopting a multidisciplinary approach and by bringing together expertise from the fields of drug delivery, molecular biology, chemistry, engineering, pharmacology and toxicology.
Das Projekt "FP1-ENVPROT 4C, Genetic Effects of Environmental Chemicals" wird/wurde gefördert durch: Kommission der Europäischen Gemeinschaften Brüssel. Es wird/wurde ausgeführt durch: Universität-Gesamthochschule Essen, Klinikum.Objective: 1) Study of molecular interactions of environmental mutagens and carcinogens at DNA level. 2) to relate biological consequences of chemical mutagens to the extent and site of reaction between the mutagens and DNA. General information: 1) using (alkyl-deoxy nucleosis)-specific MAB in combination with appropriate immunoanalytical techniques, the molecular mechanisms of the interaction of alkylating carcinogens with genomic DNA of target cells, as well as the differential capacity of mammalian (human) cells to enzymatically detect and remove specific alkylation products in/from cellular DNA will be analyzed. 2) the spectrum of high affinity mab's will be expanded to include mab's specific for some of the reaction products of alkylating agents with DNA, in particular those used in the molecular dosimetry programme. Achievements: Monoclonal antibodies (MAB) specific for several alkylated deoxyribonucleic acid (DNA) components were characterised for sensitivity and cross reactivity. These MABs were found to be highly specific and suitable for detecting alkylated DNA components in human urine samples, even in the presence of a large excess of other purines. These MABs will enable the development of a rapid monitoring system for the detection and quantitation of 3-alkyladenine in DNA, ribonucleic acid (RNA) and body fluids of individuals previously exposed to alkylating agents.
Das Projekt "PRE-ENVPROT 3C, Monoklonale Antikörper in tierischer und menschlicher DNS" wird/wurde gefördert durch: Kommission der Europäischen Gemeinschaften Brüssel. Es wird/wurde ausgeführt durch: Universitätsklinikum Essen (AöR), Institut für Zellbiologie (Tumorforschung).